Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
- Conditions
- Lupus NephritisSystemic Lupus Erythematosus
- Interventions
- Registration Number
- NCT05916781
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Brief Summary
The goal of this clinical trial is to determine whether mycophenolate mofetil(MMF) combined with tacrolimus(TAC) can maintain remission in patients with lupus nephritis (LN) who have reached treatment targets after steroid tapering. The main question\[s\] it aims to answer are:
* The efficacy, safety and tolerability of MMF combined with TAC regimen in the treatment of LN patients in the maintenance period.
* The influence of low-dose steroid on carotid intima thickness (CIMT).
* The omics and cell-free RNA (cfRNA) spectral differences related to lupus flare.
* The differences in health economics between steroid tapering and steroid maintenance patients.
Participants will be randomly assigned into 2 groups. In the steroid tapering group, participants will take MMF+TAC treatment without steroid for 1 year, and participants who stop steroid treatment without lupus flare will be randomly assigned to monotherapy with MMF or TAC. In the steroid maintenance group, participants will take MMF+TAC+steroid for 1 year, and participants without lupus flare will stop the use of steroid for 6 months. Participants without lupus flare after the stop of steroid will be randomly assigned to monotherapy with MMF or TAC.
- Detailed Description
According to the references, with the maintenance of steroid, 1-year lupus flare rate is 7%. Investigators plan to take a 2-year follow-up for participants, so the proportion of patients without flare in steroid maintenance group should be 86%. As this is a non-inferiority study, investigators hypothesize that in steroid tapering group, the proportion of patients without flare is also 86%. Investigators set α=0.05 (two-sided), 1-β=0.90, non-inferiority value = 15%, the dropout rate = 20%. The sample size of each group should be 110, the 220 in total.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 220
- Systemic lupus erythematosus participants diagnosed with 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria, fulfilled with American College of Rheumatology (ACR) lupus nephritis definition, and have reached treatment target (accord with lupus nephritis clinical remission and DORIS) for at least 6 months. The target is defined as: (1)24h urine protein ≤0.5g/d；(2)stable of improved renal function (baseline creatinine ±10% or decrease 15%)；(3)clinical SLE Disease Activity Index (cSLEDAI) =0 (all scores are required zero, except hypocomplementemia and anti-dsDNA antibody positivity)；(4)PGA score (Physician Global Assessment)<0.5; (5)prednisone or equivalent steroid dose≤5mg/d；(6)stable use of immunosuppressants and antimalarial drugs; (7)no use of biological agents.
- According to the physician, the participant can accept this treatment.
- The participant is willing to join this clinical trial, has good compliance, and could understand and sign the informed consent before the study begins.
- SLE complicated with important organ dysfunction, including consciousness disorder, cognitive disorder, renal dysfunction, heart dysfunction (NYHA class 3, 4), pulmonary arterial hypertension, and interstitial lung disease.
- SLE with active vital organ disease (not satisfied with DORIS), including but not limited to active neuropsychiatric systemic lupus erythematosus, lupus nephritis, thrombocytopenia, hemolytic anemia, myocardial involvement, gastrointestinal involvement, etc.
- Participants who are allergic to or intolerant with mycophenolate mofetil or tacrolimus.
- Participants with acute and chronic infections requiring anti-infective treatment, including but not limited to tuberculosis infection, Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection, Human Immunodeficiency Virus (HIV) infection, and Cytomegalovirus (CMV) infection.
- Participants who are pregnant or planning to become pregnant.
- Participants who have used biological agents within 6 months before enrollment.
- The researcher considers any condition that may cause the participant to be unable to complete the study or bring an obvious risk to the participant.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description steroid tapering group Glucocorticoid 0\~6th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 6th\~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) 18th\~30th month: Participants who stop steroid treatment and do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus steroid maintenance group Glucocorticoid 0\~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 18th\~24th month: Participants who do not flare will stop the use of steroid. 24th\~30th month: Participants who do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus steroid tapering group Mycophenolate Mofetil 0\~6th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 6th\~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) 18th\~30th month: Participants who stop steroid treatment and do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus steroid tapering group Tacrolimus 0\~6th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 6th\~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) 18th\~30th month: Participants who stop steroid treatment and do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus steroid maintenance group Mycophenolate Mofetil 0\~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 18th\~24th month: Participants who do not flare will stop the use of steroid. 24th\~30th month: Participants who do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus steroid maintenance group Tacrolimus 0\~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 18th\~24th month: Participants who do not flare will stop the use of steroid. 24th\~30th month: Participants who do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus
- Primary Outcome Measures
Name Time Method The 1-year flare rate of lupus nephritis participants who reach the treatment target and accept MMF+TAC remedy tapering steroid in the maintenance period. 6th~18th month If the DORIS (Definition of Remission In SLE) is not sustained, the patient is considered to have lupus flare.
Lupus flare can be further evaluated according to SELENA-SLEDAI Flare Index (SFI).
Lupus nephritis flare can be further evaluated as flare of proteinuria and flare of nephritis.
- Secondary Outcome Measures
Name Time Method Differences in medical charges between steroid tapering and steroid maintenance patients. 6th~30th month Obtain the information by questionnaire.
The changes of serum activity markers (anti-dsDNA antibody and C3 level) in SLE patients after steroid tapering. 6th~30th month Proportion of SLE patients with irreversible organ damage (assessed by SLICC/SDI) after steroid tapering. 6th~30th month The 1-year flare rate of lupus nephritis participants who accept MMF or TAC monotherapy. 18th~30th month If the DORIS (Definition of Remission In SLE) is not sustained, the patient is considered to have lupus flare.
Lupus flare (as assessed by SLEDAI and PGA) in SLE patients during the maintenance period after steroid tapering. 6th~30th month Changes in carotid intima-media thickness after steroid tapering. 6th~30th month Differences in health-related quality of life between steroid tapering and steroid maintenance patients. 6th~30th month Evaluate health-related quality of life by Short-Form Six-Dimension (SF-6D) health index. SF-6D includes 6 dimensions: physical functioning, role limitations, social functioning, pain, mental health, and vitality. The minimum total value is 0. The maximum total value is 1. Higher scores mean a better outcome.
Trial Locations
- Locations (1)
Peking Union Medical College Hospital
🇨🇳Beijing, China